NBIX Biotechnology · Neurology · Rare disease · Commercial biotech · Thesis updated July 12, 2026

Three pillars, one legal overhang

INGREZZA is still the main business, with $657 million of Q1 2026 sales.
CRENESSITY has become a real second engine, reaching $153 million in Q1 2026 sales.
The Soleno deal adds VYKAT XR and gives Neurocrine another rare disease product.
Management is spending hard on sales teams, so slower growth could hurt margins.
The DOJ inquiry into INGREZZA sales and marketing remains the biggest unknown.

01 Running thesis

Growth is real, risk is unresolved

Neurocrine is no longer a one-drug story. INGREZZA remains the anchor, but CRENESSITY is growing fast after launch. Q1 2026 net product sales passed $800 million for the first time, helped by both products.

The bull case is simple. INGREZZA keeps adding patients, CRENESSITY is acting like a second blockbuster, and VYKAT XR adds a third commercial pillar through the Soleno deal. That gives Neurocrine more ways to grow before its 2027 pipeline readouts arrive.

The bear case is also clear. The Department of Justice is looking into INGREZZA sales and marketing, and the company has not given a clear update on size, timing, or possible cost. At the same time, Neurocrine is raising SG&A, which means sales growth needs to stay strong.

May 2026→Q1 2026 confirmed the current story. INGREZZA and CRENESSITY kept growing, the Soleno deal was on track, and there was no new detail on the DOJ investigation.

Feb 2026▲CRENESSITY's first full year showed blockbuster potential, reducing reliance on INGREZZA. The offset was higher planned SG&A spending to support both sales forces.

Oct 2025→CRENESSITY sales jumped, and management chose to spend more on sales expansion. The new DOJ investigation into INGREZZA marketing added a serious overhang.

Jul 2025▲CRENESSITY sales more than tripled from Q1 to Q2 2025. INGREZZA guidance was narrowed as payer pricing pressure became more visible.

May 2025▲INGREZZA posted record new patient starts, and CRENESSITY showed an encouraging first full quarter of launch. These data points supported the move toward a multi-product business.

Feb 2025→Crinecerfont approval moved Neurocrine beyond a single-product setup. INGREZZA guidance also pointed to slower growth, raising the bar for commercial execution.

Oct 2024▲The initial thesis centered on INGREZZA's strong growth, the expected crinecerfont launch, and a late-stage psychiatry pipeline moving into Phase III.

02 Business model

Specialty drugs, heavy sales effort

Neurocrine makes money by selling branded medicines to small or specialized patient groups. INGREZZA treats tardive dyskinesia and Huntington's disease chorea. CRENESSITY treats congenital adrenal hyperplasia, a rare hormone disorder.

This is a commercial biotech model. The company spends on field teams, patient support, payer access, and medical education so doctors can find more patients and insurers will cover the drugs. That can create strong revenue growth, but it also raises fixed costs.

The weak point is leverage. If INGREZZA growth slows in the second half of 2026, if CRENESSITY demand cools, or if VYKAT XR uptake is weaker than hoped, the extra sales spending could pressure earnings. The balance sheet helps, but it does not remove that risk.

03 Product portfolio

Products that carry the story

Cash cow

INGREZZA

INGREZZA is the flagship product and biggest source of sales. It is approved for tardive dyskinesia and chorea linked to Huntington's disease.

Growth engine

CRENESSITY

CRENESSITY treats congenital adrenal hyperplasia. It launched in Q1 2025 and reached $153 million of Q1 2026 sales.

Growth engine

VYKAT XR

VYKAT XR treats Prader-Willi syndrome. The Soleno acquisition added this rare disease asset to Neurocrine's commercial base.

Option

Osuvampator

Osuvampator is in Phase III studies for major depressive disorder. Top-line results are expected in 2027.

Option

Direclidine

Direclidine is in Phase III testing for schizophrenia. The first top-line Phase III result is expected in 2027.

Option

Early and mid-stage pipeline

Neurocrine also has muscarinic programs, VMAT2 follow-ons, gene therapy collaborations, and other early research assets. These are longer-term bets.

04 Business segments

Q1 sales mix is still INGREZZA-led

INGREZZA81%modest

CRENESSITY19%growing fast

The mix uses Q1 2026 net product sales: $657 million for INGREZZA and $153 million for CRENESSITY, against $811 million total net product sales. VYKAT XR was added after that filing period, so it is not in this mix.

05 Risk factors

What could break the thesis

DOJ investigation

High impact · Medium odds

In August 2025, Neurocrine received a Civil Investigative Demand, which is a legal request for documents, from the Department of Justice. The request relates to INGREZZA sales, marketing, and promotion. A bad outcome could mean fines, a corporate integrity agreement, or limits on sales practices.

We watchAny 10-Q or 10-K update on the DOJ inquiry, any reserve accrual, or any settlement language.

Sales spending outruns growth

High impact · Medium odds

Neurocrine is investing heavily in SG&A to expand sales teams for INGREZZA and CRENESSITY. That is fine while prescriptions rise. If growth slows, those costs can turn into margin pressure fast.

We watchQuarterly SG&A growth versus net product sales growth.

INGREZZA growth moderation

High impact · Medium odds

INGREZZA is still the largest product. Q1 2026 was strong, but full-year guidance implies growth could slow later in the year. Payer pressure and competition can also hurt net price.

We watchINGREZZA quarterly sales versus the $2.7 billion to $2.8 billion 2026 guidance range.

Rare disease launch risk

Medium impact · Medium odds

CRENESSITY has launched well, and VYKAT XR adds another rare disease product. But rare disease launches depend on finding patients, winning reimbursement, and keeping patients on therapy. Early demand can look strong before the longer-term run rate is clear.

We watchNew enrollment forms, reimbursement rates, persistency, and first reported VYKAT XR sales under Neurocrine.

2027 pipeline misses

Medium impact · Medium odds

Osuvampator and direclidine are important for the next leg of growth. Both are still clinical-stage assets, so trial failure remains possible. A miss would not break today's commercial business, but it would cut future optionality.

We watchPhase III enrollment updates and the first top-line results expected in 2027.

06 Quick answers

In one breath

What does Neurocrine Biosciences sell?

Neurocrine sells branded medicines for neurological, endocrine, and psychiatric disorders. Its biggest product is INGREZZA, and its newer growth products are CRENESSITY and VYKAT XR.

Why does INGREZZA matter so much to NBIX?

INGREZZA produced $657 million of Q1 2026 sales, making it the main driver of the company. That scale funds sales investments, acquisitions, and pipeline work.

What is the main risk for NBIX stock?

The biggest specific risk is the DOJ investigation into INGREZZA sales and marketing. The other key risk is that the company is spending more on sales teams, so any slowdown in product growth could hurt margins.

When could the pipeline matter?

The next major pipeline moments are expected in 2027. Neurocrine expects top-line Phase III results for osuvampator in major depressive disorder and direclidine in schizophrenia.